Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and NovaBay Pharma (NYSE:NBY).
Madrigal Pharmaceuticals Inc (MDGL)
In a report released yesterday, Yasmeen Rahimi from Roth Capital reiterated a Buy rating on Madrigal Pharmaceuticals Inc, with a price target of $392. The company’s shares closed yesterday at $244.61.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 55.6% and a 57.1% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, Enanta Pharmaceuticals, and Evofem Biosciences Inc.
Currently, the analyst consensus on Madrigal Pharmaceuticals Inc is a Strong Buy with an average price target of $319.83, a 30.8% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $300 price target.
.
See today’s analyst top recommended stocks >>
NovaBay Pharma (NBY)
Roth Capital analyst Scott Henry reiterated a Hold rating on NovaBay Pharma yesterday and set a price target of $2.75. The company’s shares closed yesterday at $2.18, close to its 52-week low of $2.
According to TipRanks.com, Henry is a 4-star analyst with an average return of 4.1% and a 44.5% success rate. Henry covers the Healthcare sector, focusing on stocks such as Titan Pharmaceuticals, Viking Therapeutics, and Lemaitre Vascular.
NovaBay Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
